{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:45:47Z","timestamp":1791305147207,"version":"4.3.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.eclinm.2023.102318","type":"journal-article","created":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T12:11:48Z","timestamp":1700395908000},"page":"102318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-1677","authenticated-orcid":false,"given":"Felix","family":"Keil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia M.S.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Berghold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Vorburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Panny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"N\u00f6sslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3802-1339","authenticated-orcid":false,"given":"Celine","family":"Bencker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"R\u00fctti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.eclinm.2023.102318_bib1","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.eclinm.2023.102318_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.eclinm.2023.102318_bib3","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","article-title":"Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years","volume":"56","author":"Passweg","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102318_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102318_bib5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102318_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4 Suppl 13","key":"10.1016\/j.eclinm.2023.102318_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/sonc.2002.34873","article-title":"In\u00a0vitro studies with bendamustine: enhanced activity in combination with rituximab","volume":"29","author":"Rummel","year":"2002","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102318_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/bjh.15901","article-title":"Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia\u2013an updated meta-analysis","volume":"186","author":"Vidal","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102318_bib9","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102318_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93516-x","article-title":"BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy","volume":"11","author":"Hahn","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102318_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/ejh.13102","article-title":"High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity","volume":"101","author":"Noesslinger","year":"2018","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102318_bib12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ajh.25077","article-title":"Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers","volume":"93","author":"Chantepie","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102318_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2015.257","article-title":"Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity","volume":"51","author":"Garciaz","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.eclinm.2023.102318_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.clml.2019.10.015","article-title":"Impact of the conditioning regimen dose intensity before autologous stem cell transplantation on the pulmonary function test abnormalities in patients with lymphoma and multiple myeloma: single center experience","volume":"20","author":"Bou Akl","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"10.1016\/j.eclinm.2023.102318_bib15","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00247-018-4223-8","article-title":"Radiologic evaluation of pulmonary injury following carmustine- and cyclophosphamide-based preparative regimen for autologous peripheral blood stem cell transplantation in children","volume":"48","author":"Kim","year":"2018","journal-title":"Pediatr Radiol"},{"issue":"21","key":"10.1016\/j.eclinm.2023.102318_bib16","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1182\/bloodadvances.2021004863","article-title":"The impact of pulmonary function in patients undergoing autologous stem cell transplantation","volume":"5","author":"Duque-Afonso","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.eclinm.2023.102318_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/ajrccm.161.1.9903059","article-title":"Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support","volume":"161","author":"Bhalla","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.eclinm.2023.102318_bib18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/annonc\/mdh311","article-title":"A\u00a0prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment","volume":"15","author":"Dimopoulou","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102318_bib19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cncr.10182","article-title":"A\u00a0prospective study of pulmonary function in patients treated with paclitaxel and carboplatin","volume":"94","author":"Dimopoulou","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.eclinm.2023.102318_bib20","doi-asserted-by":"crossref","first-page":"E296","DOI":"10.1002\/ajh.24318","article-title":"The Dinakara equation for adjusting DLCO for hemoglobin in the HCT-CI is superior to the Cotes equation for predicting high-risk patients in allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Shibasaki","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102318_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"27","key":"10.1016\/j.eclinm.2023.102318_bib22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.eclinm.2023.102318_bib23","series-title":"Common terminology criteria for adverse events (CTCAE) version 4.0","year":"2010"},{"key":"10.1016\/j.eclinm.2023.102318_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.eclinm.2023.102318_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41409-022-01596-8","article-title":"Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study","volume":"57","author":"Costes-Tertrais","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102318_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bmt.1702154","article-title":"Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies","volume":"25","author":"Alessandrino","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102318_bib27","first-page":"335","article-title":"High-dose carmustine, etoposide and melphalan ('BEM\u2019) with autologous stem cell transplantation: a dose-toxicity study","volume":"17","author":"Ager","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"0","key":"10.1016\/j.eclinm.2023.102318_bib28","article-title":"Impact of implementing a bendamustine-based conditioning regimen on outcomes of autologous stem cell transplantation in lymphoma while novel cellular therapies emerge","volume":"0","author":"Lachance","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.eclinm.2023.102318_bib29","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/bjh.17279","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres","volume":"192","author":"Ghesqui\u00e8res","year":"2021","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102318_bib30","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/s41409-019-0508-2","article-title":"High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients","volume":"54","author":"Prediletto","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.eclinm.2023.102318_bib31","first-page":"113","article-title":"Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation","volume":"22","author":"Frankiewicz","year":"2018","journal-title":"Contemp Oncol Poznan Pol"},{"issue":"11","key":"10.1016\/j.eclinm.2023.102318_bib32","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2005-01-0035","article-title":"Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the\u00a0Bone Marrow Transplant Survivor Study","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.eclinm.2023.102318_bib33","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated\u00a0glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.eclinm.2023.102318_bib34","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) versus BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning regimen before autologous haematopoietic cell transplantation: a systematic review and meta-analysis","volume":"32","author":"Wu","year":"2023","journal-title":"Cell\u00a0Transplant"},{"issue":"9","key":"10.1016\/j.eclinm.2023.102318_bib35","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.eclinm.2023.102318_bib36","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.21.02372","article-title":"Trends in late mortality and life expectancy after autologous blood or marrow transplantation over three decades: a BMTSS report","volume":"40","author":"Bhatia","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:23:56Z","timestamp":1762899836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023004959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":36,"alternative-id":["S2589537023004959"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102318","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BendaEAM versus BEAM as conditioning regimen for ASCT in patients with relapsed lymphoma (BEB): a multicentre, randomised, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102318"}}